AGENUS INC (AGEN)

US00847G8042 - Common Stock

7.42  +0.96 (+14.86%)

After market: 7.42 0 (0%)

News Image
12 days ago - Chartmill

These stocks are moving in today's session

Friday's session: top gainers and losers

News Image
12 days ago - Chartmill

Friday's session: top gainers and losers

Top movers in Friday's session

News Image
13 days ago - Chartmill

Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.

Let's have a look at the gap up and gap down stocks in today's session.

News Image
16 days ago - Chartmill

Let's take a look at the stocks that are in motion in today's session.

Top movers in Monday's session

News Image
17 days ago - Chartmill

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.

News Image
17 days ago - InvestorPlace

Today‚Äôs Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!

News Image
17 days ago - The Motley Fool

Down 75%. Is Agenus Stock a Buy on the Dip?

Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.

News Image
22 days ago - The Motley Fool

2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?

These stocks could rocket higher, but they also present significant risks.

News Image
a month ago - InvestorPlace

3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million

If you want the chance at possible absurd returns, then consider gambling on these stocks to turn $1,000 into $1 million.

News Image
a month ago - The Motley Fool

Agenus (AGEN) Q4 2023 Earnings Call Transcript

AGEN earnings call for the period ending December 31, 2023.

News Image
2 months ago - The Motley Fool

Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today

The company hopes to engineer a 1-for-20 reverse stock split.

News Image
2 months ago - Seeking Alpha

Ginkgo stock gains after $31M contract win with Agenus

SaponiQx, a unit of Agenus (AGEN), and Ginkgo Bioworks (DNA) have won a multi-year contract worth up to $31M to sudy vaccine adjuvants. Read more here.

News Image
2 months ago - Ginkgo Bioworks

Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design

/PRNewswire/ -- The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program...

News Image
3 months ago - Seeking Alpha

Moderna RSV vaccine lags rival shots in long-term efficacy

TD Cowen argues that Moderna's (MRNA) upcoming mRNA-based RSV vaccine has a faster decline in efficacy compared to rival shots from Pfizer (PFE) and GSK (GSK). Read more here.

News Image
3 months ago - Seeking Alpha

GSK RSV shot under FDA priority review for label expansion

GSK's respiratory syncytial virus (RSV) vaccine, Arexvy, is under priority review by the FDA for a label expansion to age group 50-59. Read more here.

News Image
3 months ago - InvestorPlace

7 Analyst-Backed Stocks With Promising 10-Bagger Potential

Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot.

News Image
3 months ago - Seeking Alpha

GSK Q4 to spotlight vaccine business amid Arexvy rollout

GSK's (GSK) Q4 2023 results are exected to highlight its vaccine division amid the ongoing early market rollout of its RSV vaccine, Arexvy. Read more here.

News Image
3 months ago - InvestorPlace

3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024

There are several potential biotech breakthroughs likely to occur in 2024, and these three biotech stocks could see substantial gains

News Image
3 months ago - Seeking Alpha

Agenus stock up 7% on positive data for colorectal cancer drugs (NASDAQ:AGEN)

Agenus (AGEN) stock climbed 7% after the company announced positive results from a study of the drug combination botensilimab and balstilimab in the treatment of colorectal cancer.